Why This Hair Restoration Biotech's Shares Are Soaring

Veradermics, a pharmaceutical company focusing on skin therapies, has seen its shares surge by 268% since its initial public offering (IPO) on February 4. The company's lead treatment, VDPHL01, holds promise as a non-hormonal oral therapy for pattern hair loss, with the potential to be FDA-approved in the near future. Despite not being profitable and only possessing one drug in its pipeline, three factors suggest the stock may have further upward potential.

Firstly, Veradermics has recently published favorable phase 3 data for VDPHL01, an extended-release minoxidil formulation. The drug achieved all primary and secondary objectives in the study. Notably, 78.8% of patients taking the daily dose and 85% of those on the twice-daily dose reported improvements in hair coverage on the Androgenetic Alopecia Impact Rating Scale (AAIRS), compared to only 35.3% in the placebo group.

Approval of VDPHL01 would be groundbreaking, as it would be the first oral minoxidil, marking the first new FDA-approved hair restoration drug in nearly three decades. This alternative to finasteride, the only existing oral prescription for hair loss, would be attractive due to its lack of hormonal side effects.

Secondly, the company's market potential is substantial. Nonscarring alopecia, the most prevalent form of hair loss, affects 50 million men and 30 million women in the U.S., with over half of men and more than 40% of women experiencing some degree of hair thinning by age 50. Veradermics estimates this market to reach over $30 billion by 2028.

Minoxidil, the active ingredient in the popular hair-loss product Rogaine, is the core component of VDPHL01. The extended-release gel matrix formulation aims to enhance efficacy and safety by ensuring sustained absorption and avoiding peak minoxidil concentrations, thereby reducing the risk of side effects associated with higher concentrations.

Lastly, Veradermics is in a financially stable position despite not generating revenue yet. Post-IPO, the company has $820 million in cash available, which is sufficient to cover operations until 2030. This ample liquidity ensures it can complete necessary regulatory submissions and prepare for commercial launch, mitigating the risk of stock dilution in the short term.

Additionally, Wall Street analysts have an average price target of $170 for the stock, with a majority holding a buy or strong buy rating. However, the stock is expected to remain volatile until the company starts generating revenue.